Abstract
A 65-year-old male with 40-pack year smoking history presented with exertional dyspnea and was subsequently diagnosed with bronchiolo-alveolar carcinoma (BAC). He did not respond to first line therapy with geftinib, but he achieved disease stabilization with gemcitabine and carboplatin for 4 months before developing symptomatic worsening requiring oxygen supplementation. He responded dramatically to bortezomib with rapid symptom improvement. The follow-up computerized tomography revealed partial response that was maintained for 11 months. Based on observations like this and those seen in phase I studies with bortezomib, this agent is being studied now in patients with bronchio-alevolar cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 257-259 |
| Number of pages | 3 |
| Journal | Lung Cancer |
| Volume | 51 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2006 |
Keywords
- Bortezomib
- Bronchiolo-alveolar carcinoma
- Non-small cell lung cancer
Fingerprint
Dive into the research topics of 'Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC): A case report'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver